CHPA “Neutral” On Requiring Deadlines For TEA Reviews
This article was originally published in The Tan Sheet
CHPA comments on the Senate HELP Committee’s draft legislation to require FDA to establish review deadlines for TEAs. The trade group says it is “neutral” about the suggestion, but offers to help the committee with “more comprehensive reviews of OTC approvals.”
You may also be interested in...
FDA says it needs additional data from L’Oreal on safety, efficacy and adverse events to determine GRASE for drometrizole trisiloxane.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.